A veteran executive sees a wave of M&A coming — and a commercial future for gene editing

What's new in pharma

November 21, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Google Ventures STAT+ | Veteran biotech executive sees a wave of M&A coming — and a commercial future for gene editing At GV, Google's investment arm, venture capitalist David Schenkein oversees a team investing $1B in life sciences annually. By Allison DeAngelis STAT+ | Recursion's incoming CEO: Beyond hype on AI-driven drug development, it's time to show results Najat Khan, who was hired as Recursion's chief commercial officer and R&D head, is set to take the reins as CEO in the new year.  By Andrew Joseph Opinion: The Trump administration is turning drug review into make-a-deal The FDA Commissioner's National Priority Voucher program turns drug review into make-a-deal. By Daniel Carpenter, Thomas Hwang, and Aaron S. Kesselheim How Mark Cuban plans to 'f— up' health care STAT reporters chat with Mark Cuban about Cost Plus Drugs, his thoughts on the direct-to-consumer trend, and why he thinks TrumpRx is good. By Elaine Chen, Adam Feuerstein, and Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser